Abstract: Xerogel films on substrates are provided containing pharmaceutically active compounds. Articles incorporating such films are robust, release active compounds at predictable rates and may provide such release for relatively long periods of time. Orthopedic and trauma uses are indicated along with generalized use in contact with body fluids or as biological implants. Methods for fabrication of such films and devices are provided.
Type:
Grant
Filed:
August 28, 2006
Date of Patent:
December 14, 2010
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy. Specific second active ingredients are capable of affecting or improving blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
Abstract: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound is used as an active ingredient.
Abstract: Compositions and methods for the regulation of sleep and circadian rhythms are provided. The compositions are nutritional supplements containing melatonin and one or more vitamins that enhance the effectiveness of melatonin. Preferred vitamins include folic acid, riboflavin (vitamin B2), cobalamin (vitamin B12) or pyridoxine (vitamin B6). The compositions beneficially and advantageously regulate sleep when administered to an individual and are administered to a human or animal suffering from an irregular sleep or circadian rhythm or are administered in anticipation of the development of such an irregularity.
Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.
Type:
Grant
Filed:
May 22, 2008
Date of Patent:
August 31, 2010
Assignee:
Bellus Health (International) Limited
Inventors:
Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
Abstract: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
August 24, 2010
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A cosmetic composition is provided which includes hydrophilic composite particles of an organic sunscreen agent, particles of a crosslinked silicone elastomer, and a cosmetically acceptable carrier. The hydrophilic composite particles are formed as a composite of sunscreen agent and binder in a relative weight ratio of about 5:1 to about 1:10. The composition exhibits relatively high SPF photoprotection while maintaining excellent soft focus properties that hide skin imperfections.
Abstract: L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration.
Abstract: The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent.
Abstract: A stable pharmaceutical composition for oral administration comprising atorvastatin and an amount of a pharmaceutically acceptable organic alkalizing compound capable of establishing a microenvironment for atorvastatin having a pH of at least about 5, for example 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol).
Abstract: The invention concerns amide derivatives of the Formula (I) wherein R3 is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, (1-6C)alkoxy, halogeno-(1-6C)alkyl, hydroxyl-(1-6C)alkyl, di-[(1-6C)akly]amino-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, aryl-(1-6C)alkoxy, heteroaryl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R2 is a substituent such as hydroxy and halogeno; q is 0-4; and R4 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cyt
Type:
Grant
Filed:
September 23, 2004
Date of Patent:
August 10, 2010
Assignee:
AstraZeneca AB
Inventors:
Dearg Sutherland Brown, George Robert Brown
Abstract: A mammal undergoing an ablation procedure is treated for symptoms associated with adenosine by administering one or more adenosine receptor antagonists to the mammal prior to or during the procedure.
Abstract: The present invention relates to a pharmaceutical composition for oral application comprising: i) an anthelmintic agent; ii) a first excipient having a porous structure with an inner surface of about 500 to 1500 m2/g and a surface area according to BET of up to about 5000 m2/g; as well as to a method of preparing such a composition.
Abstract: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.
Type:
Grant
Filed:
July 9, 2002
Date of Patent:
July 13, 2010
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A patch comprises a support having electrostatic properties. The periphery of the support is coated with an adhesive material, and all or part of the non-adhesive surface of the support is directly covered with at least one biologically active substance in the form of particles. The particles remain in contact with the non-adhesive part of the support as a result of the electrostatic forces.
Abstract: A prophylactic lubricant composition for use during sexual relations, includes: a) lubricant effective to reduce friction, thereby reducing the rupture of blood vessels during sexual relations, b) an effective amount of spermicidal antiseptic active against HIV and other viruses, said antiseptic destroying the human immunodeficiency virus and other viruses, said antiseptic immobilizing the sperm and reacting with vaginal mucosa to form a barrier to the penetration of sperm cells into the uterus; and c) an effective amount of a fungicide to prevent the growth of fungi in the vagina which grow in the absence of natural bacterial flora destroyed by the antiseptic; said composition having no substantial detrimental effect.